Genelux Corp
SEC CIK 1231457 · GNLX · last insider filing 2026-06-18
Directors (from insider filings)
| Name | Capacity as filed | Filings |
|---|---|---|
| Tyree James L | Director | filed 2023 - 2026 |
| Smither John W | Director | filed 2023 - 2026 |
| Mirabelli Mary | Director | filed 2023 - 2026 |
| Zindrick Thomas | Director · President and CEO | filed 2023 - 2026 |
| Thomas John | Director | filed 2023 - 2026 |
| Woodward Gabe | Director | filed 2023 - 2023 |
Officers (from insider filings)
| Name | Title as filed | Filings |
|---|---|---|
| Groen Eric | General Counsel & Secretary | filed 2025 - 2026 |
| Yu Yong | VP, Clinical Trial Operations | filed 2023 - 2026 |
| Cappello Joseph | VP, Pharmaceutical Development | filed 2023 - 2026 |
| Pulisic Matthew | Chief Financial Officer | filed 2025 - 2026 |
| Smalling Ralph | Head of Regulatory | filed 2023 - 2026 |
| Litten Jason | Chief Medical Officer | filed 2026 - 2026 |
| Ryder Sean | General Counsel | filed 2023 - 2025 |
| Zak Lourie S. | Chief Financial Officer | filed 2023 - 2024 |
| Scigalla Paul | Chief Medical Officer | filed 2023 - 2024 |
| Jewett Caroline | Head of Quality | filed 2023 - 2024 |
| Samuelson Doug | Vice President, Finance | filed 2023 - 2023 |
| Zhang Qian | Associate VP, Research | filed 2023 - 2023 |
About this record
From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.
Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.